Head to Head Survey: Cytokinetics (NASDAQ:CYTK) & Tempest Therapeutics (NASDAQ:TPST)

Cytokinetics (NASDAQ:CYTK – Get Free Report) and Tempest Therapeutics (NASDAQ:TPST – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Cytokinetics and Tempest Therapeutics”s revenue, earnings per share (EPS) and valuation.

Get Cytokinetics alerts:

Tempest Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.72, indicating that its share price is 272% less volatile than the S&P 500.

Profitability

This table compares Cytokinetics and Tempest Therapeutics’ net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cytokinetics and Tempest Therapeutics, as reported by MarketBeat.

Cytokinetics currently has a consensus target price of $101.15, indicating a potential upside of 30.53%. Given Cytokinetics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than Tempest Therapeutics.

Insider and Institutional Ownership

22.5% of Tempest Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cytokinetics beats Tempest Therapeutics on 8 of the 14 factors compared between the two stocks.

About Cytokinetics

(Get Free Report)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Tempest Therapeutics

(Get Free Report)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.